These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

99 related items for PubMed ID: 10604043

  • 1. Studies on the euglycemic and hypolipidemic potentials of the novel indole analogue of thiazolidinedione, DRF 2189.
    Chakrabarti R, Vikramadithyan RK, Dileepkumar T, Kumar KB, Kumar MP, Misra P, Rao PB, Lohray VB, Lohray BB, Rajagopalan R.
    Arzneimittelforschung; 1999 Nov; 49(11):905-11. PubMed ID: 10604043
    [Abstract] [Full Text] [Related]

  • 2. Euglycemic and hypolipidemic activity of PAT5A: a unique thiazolidinedione with weak peroxisome proliferator activated receptor gamma activity.
    Vikramadithyan RK, Chakrabarti R, Misra P, Premkumar M, Kumar SK, Rao CS, Ghosh A, Reddy KN, Uma C, Rajagopalan R.
    Metabolism; 2000 Nov; 49(11):1417-23. PubMed ID: 11092504
    [Abstract] [Full Text] [Related]

  • 3. Antidiabetic and hypolipidemic potential of DRF 2519--a dual activator of PPAR-alpha and PPAR-gamma.
    Chakrabarti R, Misra P, Vikramadithyan RK, Premkumar M, Hiriyan J, Datla SR, Damarla RK, Suresh J, Rajagopalan R.
    Eur J Pharmacol; 2004 May 03; 491(2-3):195-206. PubMed ID: 15140637
    [Abstract] [Full Text] [Related]

  • 4. Novel euglycemic and hypolipidemic agents. 1.
    Lohray BB, Bhushan V, Rao BP, Madhavan GR, Murali N, Rao KN, Reddy AK, Rajesh BM, Reddy PG, Chakrabarti R, Vikramadithyan RK, Rajagopalan R, Mamidi RN, Jajoo HK, Subramaniam S.
    J Med Chem; 1998 May 07; 41(10):1619-30. PubMed ID: 9572887
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. PMT13, a pyrimidone analogue of thiazolidinedione improves insulin resistance-associated disorders in animal models of type 2 diabetes.
    Chakrabarti R, Vikramadithyan RK, Kumar MP, Kumar SK, Mamidi NV, Misra P, Suresh J, Hiriyan J, Rao CS, Rajagopalan R.
    Diabetes Obes Metab; 2002 Sep 07; 4(5):319-28. PubMed ID: 12190995
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. A novel selective peroxisome proliferator-activator receptor-gamma modulator-SPPARgammaM5 improves insulin sensitivity with diminished adverse cardiovascular effects.
    Chang CH, McNamara LA, Wu MS, Muise ES, Tan Y, Wood HB, Meinke PT, Thompson JR, Doebber TW, Berger JP, McCann ME.
    Eur J Pharmacol; 2008 Apr 14; 584(1):192-201. PubMed ID: 18346728
    [Abstract] [Full Text] [Related]

  • 12. MK-0767, a novel dual PPARalpha/gamma agonist, displays robust antihyperglycemic and hypolipidemic activities.
    Doebber TW, Kelly LJ, Zhou G, Meurer R, Biswas C, Li Y, Wu MS, Ippolito MC, Chao YS, Wang PR, Wright SD, Moller DE, Berger JP.
    Biochem Biophys Res Commun; 2004 May 28; 318(2):323-8. PubMed ID: 15120604
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. PAR-5359, a well-balanced PPARalpha/gamma dual agonist, exhibits equivalent antidiabetic and hypolipidemic activities in vitro and in vivo.
    Kim MK, Chae YN, Son MH, Kim SH, Kim JK, Moon HS, Park CS, Bae MH, Kim E, Han T, Choi HH, Shin YA, Ahn BN, Lee CH, Lim JI, Shin CY.
    Eur J Pharmacol; 2008 Oct 24; 595(1-3):119-25. PubMed ID: 18727927
    [Abstract] [Full Text] [Related]

  • 16. Identification of high-affinity binding sites for the insulin sensitizer rosiglitazone (BRL-49653) in rodent and human adipocytes using a radioiodinated ligand for peroxisomal proliferator-activated receptor gamma.
    Young PW, Buckle DR, Cantello BC, Chapman H, Clapham JC, Coyle PJ, Haigh D, Hindley RM, Holder JC, Kallender H, Latter AJ, Lawrie KW, Mossakowska D, Murphy GJ, Roxbee Cox L, Smith SA.
    J Pharmacol Exp Ther; 1998 Feb 24; 284(2):751-9. PubMed ID: 9454824
    [Abstract] [Full Text] [Related]

  • 17. Expression of peroxisome proliferator-activated receptor gamma (PPARgamma) in rat aortic smooth muscle cells.
    Iijima K, Yoshizumi M, Ako J, Eto M, Kim S, Hashimoto M, Sugimoto N, Liang YQ, Sudoh N, Toba K, Ouchi Y.
    Biochem Biophys Res Commun; 1998 Jun 18; 247(2):353-6. PubMed ID: 9642130
    [Abstract] [Full Text] [Related]

  • 18. Novel phthalazinone and benzoxazinone containing thiazolidinediones as antidiabetic and hypolipidemic agents.
    Madhavan GR, Chakrabarti R, Kumar SK, Misra P, Mamidi RN, Balraju V, Kasiram K, Babu RK, Suresh J, Lohray BB, Lohrayb VB, Iqbal J, Rajagopalan R.
    Eur J Med Chem; 2001 Jun 18; 36(7-8):627-37. PubMed ID: 11600232
    [Abstract] [Full Text] [Related]

  • 19. Metabolic effects of various antidiabetic and hypolipidaemic agents on a high-fat diet and multiple low-dose streptozocin (MLDS) mouse model of diabetes.
    Arulmozhi DK, Kurian R, Bodhankar SL, Veeranjaneyulu A.
    J Pharm Pharmacol; 2008 Sep 18; 60(9):1167-73. PubMed ID: 18718120
    [Abstract] [Full Text] [Related]

  • 20. Pharmacological and pharmacokinetic studies of the newly synthesized thiazolidinedione derivative 5-(4-(1-phenyl-1-cyclopropanecarbonylamino)benzyl)-thiazolidine-2 ,4-dio ne.
    Ueda N, Nomura Y, Muta Y, Matsuzaki Y, Hayashibe M, Ino Y, Suzuki S, Kurumi M.
    Arzneimittelforschung; 1998 Jun 18; 48(6):651-7. PubMed ID: 9689422
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.